½ÃÀ庸°í¼­
»óǰÄÚµå
1572383

»ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à ½ÃÀå, ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Biological Imaging Reagents Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 110 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ »ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à ½ÃÀåÀº ¸¸¼ºÁúȯÀÇ ¸¸¿¬ÀÇ Áõ°¡¿Í ¿¬±¸°³¹ß¿¡ ´ëÇÑ °í¾× ÅõÀÚ¿¡ ÀÇÇØ 2024-2032³â CAGR 7.3%¸¦ ³ªÅ¸³À´Ï´Ù.

»ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à »ê¾÷ÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀ¸·Î´Â Àü ¼¼°è¿¡¼­ ³ô¾ÆÁø °Ç°­ ÀνÄ, À̹Ì¡ ±â¼úÀÇ ±â¼ú ¹ßÀü, ¿µ»ó Áø´Ü ÀýÂ÷ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃãÇü ÀÇ·á¿¡ ÁßÁ¡À» µÎ¸é¼­ °í±Þ À̹Ì¡ ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ À̹Ì¡ ±â¼ú¿¡¼­ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀº Áø´Ü Á¤È®µµ¸¦ Çâ»ó½ÃÄÑ »ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¸ÖƼ¸ð´Þ À̹Ì¡ ±â¼úÀÇ È®´ë´Â »ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½ÃÄÑ »ý¹° ÀÇÇÐ ¿¬±¸, ÀÓ»ó Áø´Ü, Ä¡·á¹ý °³¹ß µîÀÇ ºÐ¾ß¸¦ º¯È­½Ã۰í ÀÖÀ¸¸ç, MRI, PET, CT, Çü±¤ Çö¹Ì°æ µîÀÇ ¸ð´Þ¸®Æ¼¸¦ °áÇÕÇÏ¿© ¸ÖƼ¸ð´Þ À̹Ì¡Àº »ý¹°ÇÐÀû °úÁ¤°ú Áúº´À» º¸´Ù ¸íÈ®Çϰí Á¤È®ÇÏ°Ô Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. Àº »ý¹°ÇÐÀû °úÁ¤°ú Áúº´À» º¸´Ù ¸íÈ®Çϰí Á¤È®ÇÏ°Ô Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¾ÇÕÀûÀÎ ¹æ¹ýÀº Áúº´À» ´õ Àß ÆÄ¾ÇÇϰí ÀÌÇØÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÖ¸ç, À̸¦ À§ÇØ ´Ù¾çÇÑ ¿µ»ó ½Ã¾àÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à ½ÃÀåÀº Á¦Ç° À¯Çüº°·Î Á¶¿µÁ¦, ±¤ÇÐ ½Ã¾à, ÇÙ ½Ã¾àÀ¸·Î ±¸ºÐµÇ¸ç, 2023³â Á¶¿µÁ¦°¡ 44.8%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áúº´ÀÇ Á¶±â ¹ß°ß°ú ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ƯÁ¤ ¿µ»ó Áø´Ü ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ÀÇ·á ½Ã½ºÅÛÀÌ Áø´ÜÀÇ Á¤È®¼ºÀ» ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ¿µ»óÀÇ ¼±¸íµµ¿Í Á¤È®µµ¸¦ ³ô¿©ÁÖ´Â ¾àǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡Àå ¸¹ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Çö´ë ÀÇÇп¡¼­ ÷´Ü ¿µ»ó Áø´Ü ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖÀ½À» ÀÔÁõÇÕ´Ï´Ù.

»ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à ½ÃÀåÀÇ ¿ëµµ¿¡´Â ÀÓ»ó Áø´Ü, ½Å¾à °³¹ß, ¿¬±¸ ¹× ±âŸ ºÐ¾ß°¡ Æ÷ÇԵǸç, ÀÓ»ó Áø´ÜÀº 2032³â±îÁö 97¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àü ¼¼°è¿¡¼­ °Ç°­ ÀνÄÀÌ ³ô¾ÆÁö°í Áúº´ÀÇ Á¶±â ¹ß°ßÀÌ ÃËÁøµÇ¸é¼­ À̹Ì¡ ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ÀÇ·á ½Ã½ºÅÛÀÌ Áø´ÜÀÇ Á¤È®¼ºÀ» ¿ì¼±½ÃÇÏ´Â °¡¿îµ¥, ¿µ»óÀÇ ¼±¸íµµ¿Í Á¤È®¼ºÀ» Çâ»ó½ÃŰ´Â ¾àǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡Àå ¸¹ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â Çö´ë ÀÇÇп¡¼­ ÷´Ü ¿µ»ó Áø´Ü ±â¼ú¿¡ ´ëÇÑ ÀÇÁ¸µµ°¡ ³ô¾ÆÁö°í ÀÖÀ½À» Áö¿øÇÕ´Ï´Ù.

ºÏ¹Ì »ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à »ê¾÷Àº 2023³â 47¾ï ´Þ·¯ ±Ô¸ð·Î ¿¬Æò±Õ 6.9% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºÏ¹Ì »ý¹°ÇÐÀû À̹Ì¡ ½Ã¾à »ê¾÷Àº ÃÖ÷´Ü À̹Ì¡ ±â¼ú°ú ½Ã¼³À» °®Ãá źźÇÑ ÀÇ·á ÀÎÇÁ¶ó¿¡ ÀÇÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ÀÎÇÁ¶ó´Â ÷´Ü À̹Ì¡ ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÒ »Ó¸¸ ¾Æ´Ï¶ó ÀÌ Áö¿ªÀ» »ýÀÇÇÐ ¿¬±¸ ¹× Çõ½ÅÀÇ ¼±µÎÁÖÀÚ·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ªÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ Çå½ÅÀº °ø°ø ¹× ¹Î°£ ÅõÀÚ¿¡ ÀÇÇØ Áö¿øµÇ¾î ÷´Ü À̹Ì¡ ±â¼ú°ú ½Ã¾àÀÇ °³¹ß ¹× äÅÃÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ¸¸¼ºÁúȯÀÇ Áõ°¡
      • ¸ÖƼ¸ð´Þ À̹Ì¡ÀÇ Ã¤Åà Ȯ´ë
      • ¿¬±¸°³¹ß ÅõÀÚÀÇ Áõ°¡
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • »óȯ ½Ã³ª¸®¿À
  • ±ÔÁ¦ »óȲ
  • ±â¼úÀû Àü¸Á
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®
  • °¸ ºÐ¼®
  • ÇâÈÄ ½ÃÀå µ¿Çâ

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Á¦Ç° À¯Çüº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Á¶¿µ½Ã¾à
  • ±¤ÇÐ ½Ã¾à
  • Çٽþà

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À̹Ì¡ ¸ð´Þ¸®Æ¼º°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • MRI
  • ÃÊÀ½ÆÄ
  • X¼± ¹× CT
  • ±¤ÇÐ À̹Ì¡
  • ÇÙÀÇÇÐ À̹Ì¡
    • PET
    • SPECT
    • ±âŸ ÇÙÀÇÇÐ ¿µ»ó¹ý

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÀÓ»ó Áø´Ü
    • Á¾¾çÇÐ
    • ¼øÈ¯±â
    • ½Å°æÇÐ
    • ±âŸ ÀÓ»ó Áø´Ü ¿ëµµ
  • Drug Discovery¿Í ÀǾàǰ °³¹ß
  • Á¶»ç¿Í Çõ½Å
  • ±âŸ ¿ëµµ

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • ¿µ»ó Áø´Ü ¼¾ÅÍ
  • ¿¬±¸¡¤Çмú±â°ü
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • Bayer AG
  • Bracco
  • Carl Zeiss
  • Cell Signaling Technology
  • Danaher
  • General Electric Company
  • Guerbet
  • Jubilant Pharmova Limited
  • Luminex Corporation
  • Nikon Corporation
  • Novartis AG
  • Olympus Corporation
  • Promega Corporation
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
KSA 24.10.25

The Global Biological Imaging Reagents Market will show a 7.3% CAGR between 2024 and 2032, fueled by the rising prevalence of chronic diseases and significant investments in research and development. Factors driving the growth of the Biological Imaging Reagents industry include the rising global health awareness, technological advancements in imaging techniques, and the increasing number of diagnostic imaging procedures. As healthcare systems worldwide emphasize early disease detection and personalized medicine, the demand for advanced imaging reagents has surged. Furthermore, the integration of AI and machine learning in imaging technologies is enhancing diagnostic accuracy, further propelling the growth of the biological imaging reagents market.

Further, the growing use of multimodal imaging techniques is boosting the demand for biological imaging reagents, transforming fields like biomedical research, clinical diagnostics, and therapeutic development. By combining modalities like MRI, PET, CT, and fluorescence microscopy, multimodal imaging offers a clearer and more precise view of biological processes and diseases. This holistic method enhances the identification and understanding of medical conditions, fueling the need for a variety of imaging reagents compatible with multiple modalities.

The overall Biological Imaging Reagents Industry is sorted based on product type, image modality, application, end use, and region.

The biological imaging reagents market is segmented by product type into contrast reagents, optical reagents, and nuclear reagents, with contrast reagents commanding a leading share of 44.8% in 2023. The growing emphasis on early disease detection and personalized medicine is driving the demand for specific imaging agents. As healthcare systems globally prioritize precision in diagnostics, the need for agents that enhance imaging clarity and accuracy becomes paramount. This trend underscores the increasing reliance on advanced imaging techniques in modern medicine.

The biological imaging reagents market's application segments include clinical diagnostics, drug discovery, research, and others, with clinical diagnostics expected to reach USD 9.7 billion by 2032. The rising global health awareness and the push for early disease detection are pivotal in driving the demand for imaging agents. As healthcare systems globally prioritize precision in diagnostics, the need for agents that enhance imaging clarity and accuracy becomes paramount. This trend underscores the increasing reliance on advanced imaging techniques in modern medicine.

North America biological imaging reagents industry, valued at USD 4.7 billion in 2023, is set to grow at a CAGR of 6.9%. North America's biological imaging reagents industry is bolstered by its robust healthcare infrastructure, characterized by state-of-the-art imaging technologies and facilities. This advanced infrastructure not only drives the demand for sophisticated imaging reagents but also positions the region as a leader in biomedical research and innovation. Furthermore, the region's commitment to R&D, backed by substantial public and private investments, accelerates the development and adoption of cutting-edge imaging technologies and reagents.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of chronic conditions
      • 3.2.1.2 Growing adoption of multi-modal imaging
      • 3.2.1.3 Increasing investments in research and development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Stringent government regulations
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
  • 3.6 Technological landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis
  • 3.9 Gap analysis
  • 3.10 Future market trends

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Contrast reagents
  • 5.3 Optical reagents
  • 5.4 Nuclear reagents

Chapter 6 Market Estimates and Forecast, By Imaging Modality, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 MRI
  • 6.3 Ultrasound
  • 6.4 X-ray and CT
  • 6.5 Optical imaging
  • 6.6 Nuclear imaging
    • 6.6.1 PET
    • 6.6.2 SPECT
    • 6.6.3 Other nuclear imaging modalities

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Clinical diagnostics
    • 7.2.1 Oncology
    • 7.2.2 Cardiology
    • 7.2.3 Neurology
    • 7.2.4 Other clinical diagnostic application
  • 7.3 Drug discovery and development
  • 7.4 Research and innovation
  • 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals
  • 8.3 Diagnostic imaging centers
  • 8.4 Research and academic institutes
  • 8.5 Pharmaceutical and biotechnology companies
  • 8.6 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Bayer AG
  • 10.2 Bracco
  • 10.3 Carl Zeiss
  • 10.4 Cell Signaling Technology
  • 10.5 Danaher
  • 10.6 General Electric Company
  • 10.7 Guerbet
  • 10.8 Jubilant Pharmova Limited
  • 10.9 Luminex Corporation
  • 10.10 Nikon Corporation
  • 10.11 Novartis AG
  • 10.12 Olympus Corporation
  • 10.13 Promega Corporation
  • 10.14 Sartorius AG
  • 10.15 Thermo Fisher Scientific Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦